Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer
December 04, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
December 02, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose to Present at BIO-Europe Conference
November 07, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting
November 06, 2019 09:54 ET
|
Aptose Biosciences, Inc.
– Company to Hold Event During ASH – – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”)...
Aptose Reports Results for the Third Quarter Ended September 30, 2019
November 05, 2019 16:02 ET
|
Aptose Biosciences, Inc.
CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call...
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
October 22, 2019 07:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...